|Bid||48.3100 x 800|
|Ask||48.3200 x 1800|
|Day's Range||48.1100 - 48.6400|
|52 Week Range||44.2800 - 58.3700|
|PE Ratio (TTM)||19.67|
|Forward Dividend & Yield||1.28 (2.63%)|
|1y Target Est||60.40|
Let's check out the Yahoo Finance charts of the day. Amazon (AMZN): Shares are up in early trade, at around .25%. Amazon is adding a curbside pickup option at Whole Foods for Prime members. Shoppers will be able to order milk, eggs and other groceries on the Prime Now app and park in reserved spaces where workers will place the items in their cars. Novo Nordisk (NVO): Shares down here at 5.34%. The Danish pharmaceutical company reported profit in line with forecasts for the second quarter, but the company said prices in the U.S, market would be lower next year. Tesla (TSLA): Shares down here, at around .68%. Tesla is on watch following Elon Musk's tweet Tuesday about possible plans to take the company private and reports of a $2 billion dollar investment in the Saudi Arabia investment fund. Members of the Tesla board said they have met "several times" to discuss Musk's desire to go private. For more on today's big stock movers check out the Final Round, live at 3:55 p.m. ET, right here on Yahoo Finance.
Aug.08 -- Lars Fruergaard Jorgensen, chief executive officer at Novo Nordisk, discusses the market reaction to earnings, drug prices in the U.S. and their M&A prospects. He speaks on "Bloomberg Markets: European Open."
In the first half of 2018, Novo Nordisk’s (NVO) human insulin generated revenues of 4.7 billion Danish kroner, a ~1% YoY (year-over-year) growth in local currencies.
Novo Nordisk’s (NVO) premix insulin segment witnessed a ~1% YoY (year-over-year) growth in local currencies in the first half of 2018 to 5.2 billion Danish kroner. That included revenues of 688 million Danish kroner, 856 million Danish kroner, 1.3 billion Danish kroner, and 1.9 billion Danish kroner in the United States, Europe, AAMEO (Africa, Asia, the Middle East, and Oceania), and China, respectively.
GlaxoSmithKline’s (GSK) Consumer Healthcare segment includes its wellness, oral health, nutrition, and skin health products. In the second quarter, the segment’s revenue grew 3% YoY (year-over-year) at constant exchange rates to ~1.8 billion British pounds, as shown in the chart below. GlaxoSmithKline bought out Novartis’s (NVS) stake in the companies’ consumer healthcare joint venture on June 1.
In the first half of 2018, Novo Nordisk’s fast-acting insulins segment generated revenues of 9.7 billion Danish kroner, reflecting a ~2% YoY (year-over-year) growth in local currencies.
Novo Nordisk’s (NVO) Victoza generated revenues of 11.7 billion Danish kroner in the first half of 2018 compared to 11.5 billion Danish kroner in the first half of 2017, a ~2% YoY (year-over-year) growth and a ~12% YoY growth in local currencies.
Novo Nordisk (NVO) reported net revenues of 54.3 billion Danish kroner in the first half of 2018 compared to 57.1 billion Danish kroner in H1 2017. That’s a ~5% YoY (year-over-year) decline.
The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers
Novo Nordisk (NVO) reports strong Q2 results. J&J (JNJ) seeks approval for new dosing regimen of multiple myeloma drug. Allergan (AGN) exercises option to buy Editas' lead ocular candidate.
Novo Nordisk (NVO) beats earnings and sales estimates in the second quarter of 2018. Majority of sales growth originated from drugs like Victoza , Ozempic , Xultophy and Saxenda.
On a per-share basis, the Bagsvaerd, Denmark-based company said it had profit of 68 cents. The drugmaker posted revenue of $4.39 billion in the period. Novo Nordisk shares have declined slightly more than ...
Lars Fruergaard Jorgensen, chief executive officer at Novo Nordisk, discusses the market reaction to earnings, drug prices in the U.S. and their M&A prospects. He speaks on "Bloomberg Markets: European ...
The Danish pharma group is facing intensifying competition over prices — particularly in the US — and while negotiations with pharmacy benefit managers and managed care organisations were progressing, it expected average prices after rebates “to be lower compared with the levels in 2018”. Lars Fruergaard Jorgensen, chief executive, said sales growth in the first half of 2018 had been driven by “solid performance of our key innovative products” — Saxenda for obesity and Victoza, Tresiba and Xultophy for diabetes.
Sanofi (SNY) is scheduled to announce its earnings results for the second quarter of fiscal 2018 on July 31. The company is a global pharmaceuticals player with products and therapies across the specialty areas of oncology, immunology, vaccines, multiple sclerosis, rare disease disorders, neurology, cardiovascular diseases, diabetes, and infectious diseases. As of July 25, according to a recent Reuters survey, two of the five analysts covering SNY stock have given it a “strong buy” recommendation, and three have rated it a “hold.” There are no “sell” ratings.
As we’ve already seen, Novartis (NVS) reported a 7% growth in operating revenues to ~$13.16 billion in Q2 2018. That compares to revenues of ~$12.24 billion in Q2 2017.
Sandoz, the generics arm of Novartis (NVS), is a market leader in differentiated generics. It reported nearly flat revenues at ~$2.46 billion during Q2 2018 compared to $2.45 billion during Q2 2017. Revenue growth was driven by a 2% favorable impact of foreign exchange, offset by a 2% decline in operating revenues.
As we saw in the previous part of this series, Novartis AG (NVS) surpassed Wall Street analysts’ estimates for Q2 2018 and reported revenues of ~$13.16 billion, a 7% growth YoY (year-over-year) compared to ~$12.2 billion in Q2 2017. Novartis AG, the holding company, provides healthcare solutions classified into the following three business segments: Innovative Medicines: prescription medicines Sandoz: generics Alcon: eye care
The wind farm's 72 turbines will have a rotor diameter of 167 meters and weigh almost 900 tons each. The facility, located in the Baltic Sea, is set to be in full operation by the end of 2021. Novozymes and Novo Nordisk have signed an agreement to source power from Vattenfall’s Kriegers Flak offshore wind park, the Swedish utility said Friday.
A handful of the world’s biggest drugmakers are canceling or reducing planned price increases in the U.S., following a new California drug pricing transparency law and continued political pressure over pharmaceutical costs. The California law, which began to take effect earlier this year, requires drugmakers to give insurers, governments and drug purchasers advance notice of large price increases, as a way of publicly pressuring pharmaceutical companies to keep prices down. In the past three weeks, Novartis AG, Gilead Sciences Inc., Roche Holding AG and Novo Nordisk A/S sent notices to California health plans rescinding or reducing previously announced price hikes on at least 10 drugs.